Chronic myokymia limited to the eyelid is a benign condition

Rudrani Banik, Neil R Miller

Research output: Contribution to journalArticle

Abstract

Background: Eyelid myokymia, unlike myokymia of the other facial muscles, is assumed to be a benign, self-limited disorder. However, no systematic follow-up study has been performed on patients with chronic, isolated eyelid myokymia to verify its benign nature. Methods: Retrospective single-institution chart review of 15 patients examined between 1983 and 2002 with a diagnosis of isolated eyelid myokymia who have had at least 12 months of follow-up. Results: In all patients, symptoms began as unilateral, weekly or biweekly, intermittent eyelid spasms, and progressed to daily spasms over several months. The mean duration of symptoms at first examination was 91 months (range 2.5 months to 20 years). In no patient was the myokymia the first manifestation of a neurologic disease, although one patient progressed to ipsilateral hemifacial spasm. Thirteen patients (86.7%) underwent neuroimaging that gave negative results. The myokymia resolved spontaneously in four patients. Of the remaining 11 patients, eight were treated with botulinum toxin injection at regular intervals, with most reporting an improvement in symptoms. Conclusion: Chronic isolated eyelid myokymia is a benign condition. It tends not to progress to other facial movement disorders or to be associated with other neurologic disease. It responds well to treatment with botulinum toxin.

Original languageEnglish (US)
Pages (from-to)290-292
Number of pages3
JournalJournal of Neuro-Ophthalmology
Volume24
Issue number4
DOIs
StatePublished - Dec 2004

Fingerprint

Myokymia
Eyelids
Botulinum Toxins
Nervous System Diseases
Hemifacial Spasm
Facial Muscles
Movement Disorders
Spasm
Neuroimaging

ASJC Scopus subject areas

  • Clinical Neurology
  • Ophthalmology

Cite this

Chronic myokymia limited to the eyelid is a benign condition. / Banik, Rudrani; Miller, Neil R.

In: Journal of Neuro-Ophthalmology, Vol. 24, No. 4, 12.2004, p. 290-292.

Research output: Contribution to journalArticle

@article{61b142964aa9472ab742294af3be6ebd,
title = "Chronic myokymia limited to the eyelid is a benign condition",
abstract = "Background: Eyelid myokymia, unlike myokymia of the other facial muscles, is assumed to be a benign, self-limited disorder. However, no systematic follow-up study has been performed on patients with chronic, isolated eyelid myokymia to verify its benign nature. Methods: Retrospective single-institution chart review of 15 patients examined between 1983 and 2002 with a diagnosis of isolated eyelid myokymia who have had at least 12 months of follow-up. Results: In all patients, symptoms began as unilateral, weekly or biweekly, intermittent eyelid spasms, and progressed to daily spasms over several months. The mean duration of symptoms at first examination was 91 months (range 2.5 months to 20 years). In no patient was the myokymia the first manifestation of a neurologic disease, although one patient progressed to ipsilateral hemifacial spasm. Thirteen patients (86.7{\%}) underwent neuroimaging that gave negative results. The myokymia resolved spontaneously in four patients. Of the remaining 11 patients, eight were treated with botulinum toxin injection at regular intervals, with most reporting an improvement in symptoms. Conclusion: Chronic isolated eyelid myokymia is a benign condition. It tends not to progress to other facial movement disorders or to be associated with other neurologic disease. It responds well to treatment with botulinum toxin.",
author = "Rudrani Banik and Miller, {Neil R}",
year = "2004",
month = "12",
doi = "10.1097/00041327-200412000-00003",
language = "English (US)",
volume = "24",
pages = "290--292",
journal = "Journal of Neuro-Ophthalmology",
issn = "1070-8022",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Chronic myokymia limited to the eyelid is a benign condition

AU - Banik, Rudrani

AU - Miller, Neil R

PY - 2004/12

Y1 - 2004/12

N2 - Background: Eyelid myokymia, unlike myokymia of the other facial muscles, is assumed to be a benign, self-limited disorder. However, no systematic follow-up study has been performed on patients with chronic, isolated eyelid myokymia to verify its benign nature. Methods: Retrospective single-institution chart review of 15 patients examined between 1983 and 2002 with a diagnosis of isolated eyelid myokymia who have had at least 12 months of follow-up. Results: In all patients, symptoms began as unilateral, weekly or biweekly, intermittent eyelid spasms, and progressed to daily spasms over several months. The mean duration of symptoms at first examination was 91 months (range 2.5 months to 20 years). In no patient was the myokymia the first manifestation of a neurologic disease, although one patient progressed to ipsilateral hemifacial spasm. Thirteen patients (86.7%) underwent neuroimaging that gave negative results. The myokymia resolved spontaneously in four patients. Of the remaining 11 patients, eight were treated with botulinum toxin injection at regular intervals, with most reporting an improvement in symptoms. Conclusion: Chronic isolated eyelid myokymia is a benign condition. It tends not to progress to other facial movement disorders or to be associated with other neurologic disease. It responds well to treatment with botulinum toxin.

AB - Background: Eyelid myokymia, unlike myokymia of the other facial muscles, is assumed to be a benign, self-limited disorder. However, no systematic follow-up study has been performed on patients with chronic, isolated eyelid myokymia to verify its benign nature. Methods: Retrospective single-institution chart review of 15 patients examined between 1983 and 2002 with a diagnosis of isolated eyelid myokymia who have had at least 12 months of follow-up. Results: In all patients, symptoms began as unilateral, weekly or biweekly, intermittent eyelid spasms, and progressed to daily spasms over several months. The mean duration of symptoms at first examination was 91 months (range 2.5 months to 20 years). In no patient was the myokymia the first manifestation of a neurologic disease, although one patient progressed to ipsilateral hemifacial spasm. Thirteen patients (86.7%) underwent neuroimaging that gave negative results. The myokymia resolved spontaneously in four patients. Of the remaining 11 patients, eight were treated with botulinum toxin injection at regular intervals, with most reporting an improvement in symptoms. Conclusion: Chronic isolated eyelid myokymia is a benign condition. It tends not to progress to other facial movement disorders or to be associated with other neurologic disease. It responds well to treatment with botulinum toxin.

UR - http://www.scopus.com/inward/record.url?scp=10344256712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10344256712&partnerID=8YFLogxK

U2 - 10.1097/00041327-200412000-00003

DO - 10.1097/00041327-200412000-00003

M3 - Article

C2 - 15662242

AN - SCOPUS:10344256712

VL - 24

SP - 290

EP - 292

JO - Journal of Neuro-Ophthalmology

JF - Journal of Neuro-Ophthalmology

SN - 1070-8022

IS - 4

ER -